Abstract: The present invention relates to a humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody specifically binding to CD22, a chimeric antigen receptor including the antibody, a CAR-T cell expressing the chimeric antigen receptor, a pharmaceutical composition including the same and a method for preventing or treating a disease mediated by B cells using the pharmaceutical composition. In the present invention, it was confirmed that the CD22-CAR-T cells prepared based on a humanized antibody specifically binding to CD22 effectively recognized a CD22 antigen to activate CAR-T cells, and that the CD22-CAR-T cells effectively killed cells expressing CD22. Furthermore, the humanized antibody-based CD22-CAR-T cells specifically binding to CD22 of the present invention can be usefully utilized as a composition for preventing or treating a disease related to the expression of CD22 or a disease related to B cells.
Abstract: The present invention relates to an antibody specific for CD22 and uses thereof, and more particularly to an antibody that specifically binds to CD22, a chimeric antigen receptor comprising the antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition for preventing or treating diseases mediated by cells expressing CD22 including the same. It was confirmed that the antibody selected in the present invention specifically recognized CD22-expressing cells, and the chimeric antigen receptor (CAR) and CAR-T cells targeting CD22 using the CD22-specific antibody not only effectively bound to CD22, but also activated CAR-T cells bound to CD22. In addition, since it was confirmed that the CAR-T cells of the present invention effectively kill CD22-expressing cells, the CD22-specific antibody, the chimeric antigen receptor targeting CD22, and CAR-T cells of the present invention can be usefully used as a composition for preventing or treating diseases relating to CD22 expression.
Abstract: The present invention relates to a companion diagnosis biomarker composition and a companion diagnosis kit containing the same and, particularly, to a companion diagnosis biomarker composition for predicting a therapeutic response to at least one immune checkpoint inhibitor from among a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor, and a companion diagnosis kit containing the same. According to the present invention, there is an effect that it is possible to predict a therapeutic response to at least one immune checkpoint inhibitor from among a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor not only through a companion diagnosis through cancer patient tissues, but also through proteomic analysis of cancer patient blood.
Type:
Application
Filed:
June 26, 2020
Publication date:
February 9, 2023
Applicant:
INNOBATION BIO CO., LTD.
Inventors:
Byong Chul YOO, Kyung Hee KIM, Jae Gwang PARK, Sang Myung WOO
Abstract: The present invention relates to an apparatus for diagnosing solid cancers comprising lung cancer, pancreatic cancer, bile duct cancer, colorectal cancer, breast cancer, gastric cancer, brain tumors, kidney cancer, liver cancer, and cervical cancer. More specifically, the apparatus comprises: a concentration measurement unit for measuring the concentration of each of acyl-carnitine (AC), nudifloramide (2PY), and lysophosphatidylcholine (LPC) from a biological sample; a pre-processing unit for pre-processing the measured concentrations; and a diagnosis unit for determining the diagnosis information of cancer through linear discriminant analysis using the pre-processed concentrations.
Type:
Application
Filed:
March 6, 2020
Publication date:
November 3, 2022
Applicant:
InnoBation Bio Co., Ltd.
Inventors:
Byong Chul YOO, Kyung Hee KIM, Sang Jae PARK, Sang Myung WOO, Young Ju LEE, Jun Hwa LEE, Beom Kyu CHOI
Abstract: The present invention relates to a humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody specifically binding to CD22, a chimeric antigen receptor including the antibody or a CD19xCD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition including the same for preventing or treating a disease mediated by B cells. In the present invention, it was confirmed that the CD22-CAR-T cells and bispecific CD19xCD22-CAR-T cells prepared based on a humanized antibody specifically binding to CD22 effectively recognized a CD22 antigen to activate CAR-T cells, and that the CD22-CAR-T cells and bispecific CD19xCD22-CAR-T cells effectively killed cells expressing CD22.